Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.
Khan KH, Wong M, Rihawi K, Bodla S, Morganstein D, Banerji U, Molife LR. Khan KH, et al. Among authors: rihawi k. Oncologist. 2016 Jul;21(7):855-60. doi: 10.1634/theoncologist.2015-0248. Epub 2016 May 5. Oncologist. 2016. PMID: 27151652 Free PMC article. Clinical Trial.
Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.
Coleman N, Michalarea V, Alken S, Rihawi K, Lopez RP, Tunariu N, Petruckevitch A, Molife LR, Banerji U, De Bono JS, Welsh L, Saran F, Lopez J. Coleman N, et al. Among authors: rihawi k. J Neurooncol. 2018 Aug;139(1):107-116. doi: 10.1007/s11060-018-2847-z. Epub 2018 Apr 10. J Neurooncol. 2018. PMID: 29637509 Clinical Trial.
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.
de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang JC, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkowa N, Huang DC, Bogenrieder T, Twelves C, Cheng AL. de Bono J, et al. Among authors: rihawi k. Br J Cancer. 2020 Apr;122(9):1324-1332. doi: 10.1038/s41416-020-0774-1. Epub 2020 Mar 12. Br J Cancer. 2020. PMID: 32161368 Free PMC article. Clinical Trial.
A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products.
Ferrarini A, Forcato C, Buson G, Tononi P, Del Monaco V, Terracciano M, Bolognesi C, Fontana F, Medoro G, Neves R, Möhlendick B, Rihawi K, Ardizzoni A, Sumanasuriya S, Flohr P, Lambros M, de Bono J, Stoecklein NH, Manaresi N. Ferrarini A, et al. Among authors: rihawi k. PLoS One. 2018 Mar 1;13(3):e0193689. doi: 10.1371/journal.pone.0193689. eCollection 2018. PLoS One. 2018. PMID: 29494651 Free PMC article.
Determinants of Last-line Treatment in Metastatic Breast Cancer.
Cinausero M, Gerratana L, De Carlo E, Iacono D, Bonotto M, Fanotto V, Buoro V, Basile D, Vitale MG, Rihawi K, Fasola G, Puglisi F. Cinausero M, et al. Among authors: rihawi k. Clin Breast Cancer. 2018 Jun;18(3):205-213. doi: 10.1016/j.clbc.2017.07.008. Epub 2017 Jul 14. Clin Breast Cancer. 2018. PMID: 28781022
A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
Angevin E, Spitaleri G, Rodon J, Dotti K, Isambert N, Salvagni S, Moreno V, Assadourian S, Gomez C, Harnois M, Hollebecque A, Azaro A, Hervieu A, Rihawi K, De Marinis F. Angevin E, et al. Among authors: rihawi k. Eur J Cancer. 2017 Dec;87:131-139. doi: 10.1016/j.ejca.2017.10.016. Epub 2017 Nov 14. Eur J Cancer. 2017. PMID: 29145039 Free article. Clinical Trial.
47 results